<DOC>
	<DOCNO>NCT00003566</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure thoracoscopy may help measure patient 's response previous treatment . PURPOSE : Diagnostic trial determine accuracy thoracoscopy patient stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Thoracoscopy Patients With Stage IIIA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : The purpose study test usefulness safety restaging patient 's cancer procedure call thoracoscopy . Restaging process physician measure response patient treatment . The primary secondary objective describe . OBJECTIVES : Primary Objective : 1 . Evaluate feasibility use videothoracoscopy access identify residual viable cancer mediastinal lymph node and/or evaluate condition render patient unresectable ( pleural carcinomatosis T4 primary tumor ) follow prior mediastinoscopy period neoadjuvant therapy Stage IIIA N2 non-small cell lung cancer . Secondary Objectives : 1 . Evaluate safety ( morbidity mortality ) pre-resectional , thoracoscopic restaging patient undergone prior mediastinoscopy induction therapy Stage III ( N2 ) NSCLC . 2 . Assess accuracy ( false-negative rate ) thoracoscopic mediastinal node restaging prior mediastinoscopy induction therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologic Documentation : All patient must histologic documentation Stage IIIA nonsmall cell lung cancer basis involve N2 node document mediastinoscopy perform prior induction therapy . Previously treat relapsed patient eligible . 2 . Prior Treatment : great equal 2 cycle chemotherapy without radiotherapy ( great equal 40 Gy ) radiotherapy alone ( great equal 40 Gy ) must complete within 60 day registration . 3 . No distant metastatic disease local disease progression . Patients respond stable local disease eligible . Those local disease progression define 25 % increase local tumor size appearance new area malignant disease ineligible . 4 . No previous intrapleural surgery ipsilateral side . 5 . ECOG Performance Status : 02</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>